Crossmark

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

Crossref DOI link: https://doi.org/10.1186/s12885-020-6708-8

Published Online: 2020-03-14

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sheng, Xinan

Jin, Jie

He, Zhisong

Huang, Yiran

Zhou, Aiping

Wang, Jinwan

Ren, Xiubao

Ye, Dingwei

Zhang, Xu

Qin, Shukui

Zhou, Fangjian

Wang, Binhui

Guo, Jun
Funding

Funding for this research was provided by:

GlaxoSmithKline

Novartis Pharmaceuticals Corporation
License Information

Text and Data Mining valid from 2020-03-14

Version of Record valid from 2020-03-14
More Information

Article History

Received: 8 March 2019

Accepted: 3 March 2020

First Online: 14 March 2020

Ethics approval and consent to participate

: The study protocol with any amendments, informed consent, and other information that required preapproval were reviewed and approved by the investigational center ethics committee or institutional review board in China as required.Written informed consent was obtained from each patient before performing any study-specific procedures.

: Not applicable.

: BW is an employee of Beijing Novartis Pharma Co., Ltd. All other authors have no conflict of interest to declare.

Document is current

Any future updates will be listed below